A delay integro-differential equation model fitted to pharmacokinetic and RNA-seq data indicates that a single medium-to-high dose of pembrolizumab may suffice for effective neoadjuvant eradication of locally advanced MSI-H/dMMR colorectal tumors.
A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis
2 Pith papers cite this work. Polarity classification is still indexing.
2
Pith papers citing it
representative citing papers
Sensitivity analysis using FAST and EFAST reduces a data-driven model of pembrolizumab therapy in de novo metastatic MSI-H/dMMR CRC to two simpler versions that reproduce original trajectories.
citing papers explorer
-
Optimisation of neoadjuvant pembrolizumab therapy for locally advanced MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations
A delay integro-differential equation model fitted to pharmacokinetic and RNA-seq data indicates that a single medium-to-high dose of pembrolizumab may suffice for effective neoadjuvant eradication of locally advanced MSI-H/dMMR colorectal tumors.
-
Sensitivity analysis-guided model reduction of a mathematical model of pembrolizumab therapy for de novo metastatic MSI-H/dMMR colorectal cancer
Sensitivity analysis using FAST and EFAST reduces a data-driven model of pembrolizumab therapy in de novo metastatic MSI-H/dMMR CRC to two simpler versions that reproduce original trajectories.